Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2106-2112

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rittershaus, C. W.
Right arrow Articles by Ryan, U. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rittershaus, C. W.
Right arrow Articles by Ryan, U. S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Lipid and lipoprotein metabolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2106.)
© 2000 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis

Charles W. Rittershaus; David P. Miller; Lawrence J. Thomas; Michele D. Picard; Christopher M. Honan; Constance D. Emmett; Carolyn L. Pettey; Hedy Adari; Russell A. Hammond; David T. Beattie; Allan D. Callow; Henry C. Marsh; Una S. Ryan

From AVANT Immunotherapeutics, Inc, Needham, Mass, and Boston University Medical Center (A.D.C.), Boston, Mass.

Correspondence to Charles W. Rittershaus, AVANT Immunotherapeutics, Inc, 119 Fourth Ave, Needham, MA 02494. E-mail crittershaus{at}avantimmune.com

Abstract—Using a vaccine approach, we immunized New Zealand White rabbits with a peptide containing a region of cholesteryl ester transfer protein (CETP) known to be required for neutral lipid transfer function. These rabbits had significantly reduced plasma CETP activity and an altered lipoprotein profile. In a cholesterol-fed rabbit model of atherosclerosis, the fraction of plasma cholesterol in HDL was 42% higher and the fraction of plasma cholesterol in LDL was 24% lower in the CETP-vaccinated group than in the control-vaccinated group. Moreover, the percentage of the aorta surface exhibiting atherosclerotic lesion was 39.6% smaller in the CETP-vaccinated rabbits than in controls. The data reported here demonstrate that CETP activity can be reduced in vivo by vaccination with a peptide derived from CETP and support the concept that inhibition of CETP activity in vivo can be antiatherogenic. In addition, these studies suggest that vaccination against a self-antigen is a viable therapeutic strategy for disease management.


Key Words: CETP • lipoproteins • atherosclerosis • vaccine




This article has been cited by other articles:


Home page
LupusHome page
J. Carvalho, R. Pereira, and Y. Shoenfeld
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, November 1, 2009; 18(13): 1209 - 1212.
[Abstract] [PDF]


Home page
CirculationHome page
S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Circulation, December 9, 2008; 118(24): 2506 - 2514.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
I. M. Stylianou, S. R. Langley, K. Walsh, Y. Chen, C. Revenu, and B. Paigen
Differences in DBA/1J and DBA/2J reveal lipid QTL genes
J. Lipid Res., November 1, 2008; 49(11): 2402 - 2413.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
N. J. Hime, A. S. Black, J. J. Bulgrien, and L. K. Curtiss
Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP
J. Lipid Res., October 1, 2008; 49(10): 2113 - 2123.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Guerin, W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, C. L. Shear, and M. J. Chapman
Inhibition of CETP by Torcetrapib Attenuates the Atherogenicity of Postprandial TG-Rich Lipoproteins in Type IIB Hyperlipidemia
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 148 - 154.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. J. Van Lenten, A. C. Wagner, M. Navab, G. M. Anantharamaiah, S. Hama, S. T. Reddy, and A. M. Fogelman
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits
J. Lipid Res., November 1, 2007; 48(11): 2344 - 2353.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. D. Hauer, G. H.M. van Puijvelde, N. Peterse, P. de Vos, V. van Weel, E. J.A. van Wanrooij, E. A.L. Biessen, P. H.A. Quax, A. G. Niethammer, R. A. Reisfeld, et al.
Vaccination Against VEGFR2 Attenuates Initiation and Progression of Atherosclerosis
Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 2050 - 2057.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Harder, P. Lau, A. Meng, S. C. Whitman, and R. McPherson
Cholesteryl Ester Transfer Protein (CETP) Expression Protects Against Diet Induced Atherosclerosis in SR-BI Deficient Mice
Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 858 - 864.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. K. Shah
Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
Eur. Heart J., January 1, 2007; 28(1): 5 - 12.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. H. Davidson, J. M. McKenney, C. L. Shear, and J. H. Revkin
Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels
J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1774 - 1781.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
I. M. Stylianou, S.-W. Tsaih, K. DiPetrillo, N. Ishimori, R. Li, B. Paigen, and G. Churchill
Complex Genetic Architecture Revealed by Analysis of High-Density Lipoprotein Cholesterol in Chromosome Substitution Strains and F2 Crosses
Genetics, October 1, 2006; 174(2): 999 - 1007.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Kee, D. Caiazza, K.-A. Rye, P.H.R. Barrett, L.A. Morehouse, and P.J. Barter
Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 884 - 890.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven
Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 706 - 715.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. W. Clark, R. B. Ruggeri, D. Cunningham, and M. J. Bamberger
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
J. Lipid Res., March 1, 2006; 47(3): 537 - 552.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. J. Barter and J. J.P. Kastelein
Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
D. Masson, J.-P. Pais de Barros, Z. Zak, T. Gautier, N. Le Guern, M. Assem, J. W. Chisholm, J. R. Paterniti Jr., and L. Lagrost
Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes
J. Lipid Res., February 1, 2006; 47(2): 356 - 365.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Dumont, T. Gautier, J.-P. P. de Barros, H. Laplanche, D. Blache, P. Ducoroy, J. Fruchart, J.-C. Fruchart, P. Gambert, D. Masson, et al.
Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI
J. Biol. Chem., November 11, 2005; 280(45): 38108 - 38116.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Shinohara, S. Kawashima, T. Yamashita, T. Takaya, R. Toh, T. Ishida, T. Ueyama, N. Inoue, K.-i. Hirata, and M. Yokoyama
Xenogenic smooth muscle cell immunization reduces neointimal formation in balloon-injured rabbit carotid arteries
Cardiovasc Res, November 1, 2005; 68(2): 249 - 258.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
E Toubi and Y Shoenfeld
Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?
Lupus, September 1, 2005; 14(9): 665 - 669.
[Abstract] [PDF]


Home page
CirculationHome page
J. S. Forrester, R. Makkar, and P.K. Shah
Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians
Circulation, April 12, 2005; 111(14): 1847 - 1854.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Nilsson, G. K. Hansson, and P. K. Shah
Immunomodulation of Atherosclerosis: Implications for Vaccine Development
Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 18 - 28.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
G. J. de Grooth, A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven
A review of CETP and its relation to atherosclerosis
J. Lipid Res., November 1, 2004; 45(11): 1967 - 1974.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. E. Brousseau, E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
N. Engl. J. Med., April 8, 2004; 350(15): 1505 - 1515.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. M. Gotto Jr and E. A. Brinton
Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update
J. Am. Coll. Cardiol., March 3, 2004; 43(5): 717 - 724.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. W. Clark, T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al.
Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib
Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 490 - 497.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
V. M. Paromov and R. E. Morton
Lipid Transfer Inhibitor Protein Defines the Participation of High Density Lipoprotein Subfractions in Lipid Transfer Reactions Mediated by Cholesterol Ester Transfer Protein (CETP)
J. Biol. Chem., October 17, 2003; 278(42): 40859 - 40866.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. J. Barter, H. B. Brewer Jr, M. J. Chapman, C. H. Hennekens, D. J. Rader, and A. R. Tall
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 160 - 167.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. M. Cazita, J. A. Berti, C. Aoki, M. Gidlund, L. M. Harada, V. S. Nunes, E. C. R. Quintao, and H. C. F. Oliveira
Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice
J. Lipid Res., January 1, 2003; 44(1): 33 - 40.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Z. Zak, L. Lagrost, T. Gautier, D. Masson, V. Deckert, L. Duverneuil, J.-P. P. de Barros, N. Le Guern, L. Dumont, M. Schneider, et al.
Expression of simian CETP in normolipidemic Fisher rats has a profound effect on large sized apoE-containing HDL
J. Lipid Res., December 1, 2002; 43(12): 2164 - 2171.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. S. Forrester
Prevention of Plaque Rupture: A New Paradigm of Therapy
Ann Intern Med, November 19, 2002; 137(10): 823 - 833.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Gautier, D. Masson, M. C. Jong, L. Duverneuil, N. Le Guern, V. Deckert, J.-P. P. de Barros, L. Dumont, A. Bataille, Z. Zak, et al.
Apolipoprotein CI Deficiency Markedly Augments Plasma Lipoprotein Changes Mediated by Human Cholesteryl Ester Transfer Protein (CETP) in CETP Transgenic/ApoCI-knocked Out Mice
J. Biol. Chem., August 23, 2002; 277(35): 31354 - 31363.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P.N. Durrington, B. Mackness, and M.I. Mackness
The Hunt for Nutritional and Pharmacological Modulators of Paraoxonase
Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1248 - 1250.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. Gander, P. Eller, S. Kaser, I. Theurl, D. Walter, T. Sauper, A. Ritsch, J. R. Patsch, and B. Foger
Molecular characterization of rabbit phospholipid transfer protein: choroid plexus and ependyma synthesize high levels of phospholipid transfer protein
J. Lipid Res., April 1, 2002; 43(4): 636 - 645.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II
Circulation, November 13, 2001; 104(20): 2498 - 2502.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. von Eckardstein, J.-R. Nofer, and G. Assmann
High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport
Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 13 - 27.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Barter
CETP and Atherosclerosis
Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2029 - 2031.
[Full Text] [PDF]


Home page
CirculationHome page
G. J. de Grooth, J. A. Kuivenhoven, A. F.H. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. van Tol, and J. J.P. Kastelein
Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study
Circulation, May 7, 2002; 105(18): 2159 - 2165.
[Abstract] [Full Text] [PDF]